{
  "source": "PA-Med-Nec-Ebglyss.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2367-1\nProgram Prior Authorization/Medical Necessity\nMedications Ebglyss™ (lebrikizumab-lbkz)\nP&T Approval Date 3/2025\nEffective Date 5/1/2025\n1. Background:\nEbglyss (lebrikizumab-lbkz) is an interleukin-13 antagonist indicated for the treatment of adults\nand pediatric patients 12 years of age and older who weigh at least 40 kg with moderate to\nsevere atopic dermatitis whose disease is not adequately controlled with topical prescription\ntherapies or when those therapies are not advisable. Ebglyss can be used with or without topical\ncorticosteroids.\n2. Coverage Criteriaa:\nA. Atopic Dermatitis\n1. Initial Authorization\na. Ebglyss will be approved based on all of the following criteria:\n(1) Diagnosis of moderate to severe chronic atopic dermatitis\n-AND-\n(2) History of failure, contraindication, or intolerance to two of the following\ntherapeutic classes of topical therapies (document drug, date of trial, and/ or\ncontraindication to medication)^:\n(a) Medium, high, or very-high potency topical corticosteroid [e.g., Elocon\n(mometasone furoate), Synalar (fluocinolone acetonide), Lidex (fluocinonide)]\n(b) Topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic\n(tacrolimus)]*\n(c) Eucrisa (crisaborole)*\n-AND-\n(3) Patient is not receiving Ebglyss in combination with either of the following:\n(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent\n(dupilumab)]\n(b) Janus kinase inhibitor [e.g., Cibinqo (abrocitinib), Opzelura (topical\nruxolitinib), Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib)]\n-AND-\n© 2025 UnitedHealthcare Services, Inc.\n1\n(4) Prescribed by one of the following:\n(a) Dermatologist\n(b) Allergist\n(c) Immunologist\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Ebglyss will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Ebglyss therapy\n-AND-\n(2) Patient is not receiving Ebglyss in combinatio",
    "rization\na. Ebglyss will be approved based on all of the following criteria:\n(1) Documentation of positive clinical response to Ebglyss therapy\n-AND-\n(2) Patient is not receiving Ebglyss in combination with either of the following:\n(a) Biologic immunomodulator [e.g., Adbry (tralokinumab-ldrm), Dupixent\n(dupilumab)]\n(b) Janus kinase inhibitor [e.g., Cibinqo (abrocitinib), Opzelura (topical\nruxolitinib), Rinvoq (upadacitinib), Xeljanz/XR (tofacitinib)]\n-AND-\n(3) Prescribed by one of the following:\n(a) Dermatologist\n(b) Allergist\n(c) Immunologist\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n^Tried/failed alternative(s) are supported by FDA labeling.\n* Elidel, Protopic/tacrolimus ointment, and Eucrisa require prior authorization.\n© 2025 UnitedHealthcare Services, Inc.\n2\nTable 1: Relative potencies of topical corticosteroids\nClass Drug Dosage Form Strength\n(%)\nAugmented betamethasone Ointment, gel 0.05\ndipropionate\nVery high\nClobetasol propionate Cream, foam, ointment 0.05\npotency\nDiflorasone diacetate Ointment 0.05\nHalobetasol propionate Cream, ointment 0.05\nAmcinonide Cream, lotion, ointment 0.1\nAugmented betamethasone Cream, lotion 0.05\ndipropionate\nBetamethasone dipropionate Cream, foam, ointment, solution 0.05\nDesoximetasone Cream, ointment 0.25\nHigh Potency Desoximetasone Gel 0.05\nDiflorasone diacetate Cream 0.05\nFluocinonide Cream, gel, ointment, solution 0.05\nHalcinonide Cream, ointment 0.1\nMometasone furoate Ointment 0.1\nTriamcinolone acetonide Cream, ointment 0.5\nBetamethasone valerate Cream, foam, lotion, ointment 0.1\nClocortolone pivalate Cream 0.1\nDesoximetasone Cream 0.05\nFluocinolone acetonide Cream, ointment 0.025\nMedium\nFlurandrenolide Cream, ointment, lotion 0.05\npotency\nFluticasone propionate Cream 0.05\nFluticasone propionate Ointment 0.005\nMometason",
    "ne Cream 0.05\nFluocinolone acetonide Cream, ointment 0.025\nMedium\nFlurandrenolide Cream, ointment, lotion 0.05\npotency\nFluticasone propionate Cream 0.05\nFluticasone propionate Ointment 0.005\nMometasone furoate Cream, lotion 0.1\nTriamcinolone acetonide Cream, ointment, lotion 0.1\nHydrocortisone butyrate Cream, ointment, solution 0.1\nLower-\nHydrocortisone probutate Cream 0.1\nmedium\nHydrocortisone valerate Cream, ointment 0.2\npotency\nPrednicarbate Cream 0.1\nAlclometasone dipropionate Cream, ointment 0.05\nLow potency Desonide Cream, gel, foam, ointment 0.05\nFluocinolone acetonide Cream, solution 0.01\nDexamethasone Cream 0.1\nLowest\nHydrocortisone Cream, lotion, ointment, solution 0.25, 0.5, 1\npotency\nHydrocortisone acetate Cream, ointment 0.5-1\n© 2025 UnitedHealthcare Services, Inc.\n3\nTable 2: Low, medium and high daily doses of inhaled corticosteroids\nAdults and adolescents (12 years of age and older)\nDrug Daily dose (mcg)\nLow Medium High\nBeclometasone dipropionate (CFC) 200-500 >500-1000 >1000\nBeclometasone dipropionate (HFA) 100-200 >200-400 >400\nBudesonide DPI 200-400 >400-800 >800\nCiclesonide (HFA) 80-160 >160-320 >320\nFluticasone furoate (DPI) 100 n.a 200\nFluticasone propionate (DPI) 100-250 >250-500 >500\nFluticasone propionate (HFA) 100-250 >250-500 >500\nMometasone furoate 110-220 >220-440 >440\nTriamcinolone acetonide 400-1000 >1000-2000 >2000\n3. Additional Clinical Programs:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim\nlogic. Use of automated approval and re-approval processes varies by program and/or\ntherapeutic class\n• Supply limitations may be in place\n4. References:\n1. Ebglyss [package insert]. Indianapolis, IN: Eli Lilly and Company; September 2024.\n2. Eichenfield LF, Tom WL, Chamlin SL et al. Guidelines of care for the management of atopic\ndermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad De",
    "Company; September 2024.\n2. Eichenfield LF, Tom WL, Chamlin SL et al. Guidelines of care for the management of atopic\ndermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol.\n2014; 70(1):338-51.\n3. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic\ndermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J\nAm Acad Dermatol. 2014; 71(1):116-32.\n4. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic\ndermatitis: Section 3. Management and treatment with phototherapy and systemic agents. J Am\nAcad Dermatol. 2014 Aug;71(2):327-49.\nProgram Prior Authorization/Medical Necessity - Ebglyss (lebrikizumab-lbkz)\nChange Control\n3/2025 New program.\n© 2025 UnitedHealthcare Services, Inc.\n4"
  ]
}